|
1.
|
Target Development towards First Production of High-Molar- Activity $^{44g}$Sc and $^{47}$Sc by Mass Separation at CERN-MEDICIS
/ Mamis, Edgars (CERN ; Latvia U.) ; Duchemin, Charlotte (CERN) ; Berlin, Valentina (CERN) ; Bernerd, Cyril (CERN) ; Bovigny, Mathieu (CERN) ; Chevallay, Eric (CERN) ; Crepieux, Bernard (CERN) ; Gadelshin, Vadim Maratovich (Mainz U., Inst. Phys.) ; Heinke, Reinhard (CERN) ; Hernandez, Ronaldo Mendez (CERN ; Havana, ISCTN) et al.
The radionuclides 43Sc, 44g/mSc, and 47Sc can be produced cost-effectively in sufficient yield for medical research and applications by irradiating natTi and natV target materials with protons. Maximizing the production yield of the therapeutic 47Sc in the highest cross section energy range of 24–70 MeV results in the co-production of long-lived, high-γ-ray-energy 46Sc and 48Sc contaminants if one does not use enriched target materials. [...]
2024 - 28 p.
- Published in : Pharmaceuticals 17 (2024) 390
Fulltext: PDF;
|
|
|
2.
|
Scandium thermal release from activated natTi and natV target materials in mixed particle fields: Investigation of parameters relevant for isotope mass separation
/ Mamis, E (CERN ; Latvia U.) ; Kalnina, P (CERN ; Latvia U.) ; Duchemin, C (CERN) ; Lambert, L (CERN) ; Conan, N (CERN) ; Deschamps, M (CERN) ; Dorsival, A (CERN) ; Froeschl, R (CERN) ; Ruiz, F Ogallar (CERN) ; Theis, C (CERN) et al.
Scandium (Sc) has gained significant interest in nuclear medicine due to its 43Sc, 44g/mSc, and 47Sc radioactive isotopes being suitable for cancer diagnostics and therapy, offering a promising avenue for theranostics. Various production methods, including irradiation of enriched or naturally abundant calcium (Ca), titanium (Ti), and vanadium (V) materials with different particle beams, have been investigated to produce 43Sc, 44g/mSc, and 47Sc. [...]
2024 - 10 p.
- Published in : Nucl. Instrum. Methods Phys. Res., B 553 (2024) 165400
Fulltext: PDF;
|
|
|
3.
|
CERN-MEDICIS: Operational indicators to support the production of new medical radionuclides by mass-separation
/ Stora, T (CERN) ; Duchemin, C (CERN) ; Andreazza, W (CERN) ; Aubert, E (CERN) ; Bernerd, C (CERN ; Leuven U.) ; Cocolios, T (Leuven U.) ; Deschamps, M (CERN) ; Dorsival, A (CERN) ; Duraffourg, M (CERN) ; Fedosseev, V (CERN) et al.
CERN-MEDICIS is an isotope mass separation facility for biomedical R&D; located in a class A laboratory, receiving up to 50% of the 1.4GeV PSB protons. It was commissioned with radioactive ion beams in 2017. [...]
2023 - 6 p.
- Published in : J. Phys. : Conf. Ser.: 2687 (2024) , no. 8, pp. 082039
- Published in : JACoW IPAC: 2023 (2023) , pp. WEPM125
Fulltext: PublicationJACoW - PDF; PublicationIOP - PDF;
In : 14th International Particle Accelerator Conference (IPAC 2023), Venice, Italy, 7 - 12 May 2023, pp.082039
|
|
|
4.
|
Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?
/ Radzina, Maija (Latvia U. ; CERN) ; Saule, Laura (Latvia U.) ; Mamis, Edgars (Latvia U. ; CERN) ; Koester, Ulli (Laue-Langevin Inst.) ; Cocolios, Thomas Elias (Leuven U.) ; Pajuste, Elina (Latvia U.) ; Kalnina, Marika (Unlisted) ; Palskis, Kristaps (CERN ; Riga Tech. U.) ; Sawitzki, Zoe (Leuven U.) ; Talip, Zeynep (PSI, Villigen) et al.
Background
In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe.
Main body
A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. [...]
2023 - 16 p.
- Published in : EJNMMI Radiopharm. Chem. 8 (2023) 27
Fulltext: PDF;
|
|
|
5.
|
|
|
6.
|
Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [$^{153}$Sm]Sm-DOTA-TATE
/ Vermeulen, Koen (SCK-CEN, Mol) ; Van de Voorde, Michiel (SCK-CEN, Mol) ; Segers, Charlotte (SCK-CEN, Mol) ; Coolkens, Amelie (SCK-CEN, Mol) ; Pérez, Sunay Rodriguez (SCK-CEN, Mol) ; Daems, Noami (SCK-CEN, Mol) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Crabbé, Melissa (SCK-CEN, Mol) ; Opsomer, Tomas (SCK-CEN, Mol) ; Vargas, Clarita Saldarriaga (SCK-CEN, Mol) et al.
Samarium-153 is a promising theranostic radionuclide, but low molar activities (Am) resulting from its current production route render it unsuitable for targeted radionuclide therapy (TRNT). Recent efforts combining neutron activation of $^{152}$Sm in the SCK CEN BR2 reactor with mass separation at CERN/MEDICIS yielded high-Am $^{153}$Sm. [...]
2022 - 15 p.
- Published in : Pharmaceutics 14 (2022) 2566
Fulltext: PDF;
|
|
|
7.
|
|
|
8.
|
Resonant laser ionization and mass separation of $^{225}$Ac
/ Johnson, Jake D (Leuven U.) ; Heines, Michael (Leuven U.) ; Bruchertseifer, Frank (Geel, JRC) ; Chevallay, Eric (CERN) ; Cocolios, Thomas E (Leuven U.) ; Dockx, Kristof (Leuven U.) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Heinitz, Stephan (SCK-CEN, Mol) ; Heinke, Reinhard (Leuven U. ; CERN) ; Hurier, Sophie (Leuven U. ; SCK-CEN, Mol) et al.
$^{225}$Ac is a radio-isotope that can be linked to biological vector molecules to treat certain distributed cancers using targeted alpha therapy. However, developing $^{225}$Ac-labelled radiopharmaceuticals remains a challenge due to the supply shortage of pure $^{225}$Ac itself. [...]
2023 - 11 p.
- Published in : Sci. Rep. 13 (2023) 1347
Fulltext: PDF;
|
|
|
9.
|
Half-life determination of $^{155}$Tb from mass-separated samples produced at CERN-MEDICIS
/ Collins, S M (Teddington, Natl. Phys. Lab ; Surrey U.) ; Robinson, A P (Teddington, Natl. Phys. Lab) ; Ivanov, P (Teddington, Natl. Phys. Lab) ; Köster, U (Laue-Langevin Inst.) ; Cocolios, T E (Leuven U.) ; Russell, B (Teddington, Natl. Phys. Lab) ; Webster, B (Teddington, Natl. Phys. Lab ; Surrey U.) ; Fenwick, A J (Teddington, Natl. Phys. Lab) ; Duchemin, C (Leuven U. ; CERN) ; Ramos, J P (Leuven U. ; CERN ; Belgian Ceramic Res. Ctr., Mons) et al.
Terbium-155 has been identified for its potential for single-photon emission computed tomography (SPECT) in nuclear medicine. For activity measurements, an accurate and precise half-life of this radionuclide is required. [...]
2022 - 11 p.
- Published in : Appl. Radiat. Isot. 190 (2022) 110480
|
|
|
10.
|
Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS
/ Heinke, Reinhard (CERN ; Leuven U.) ; Chevallay, Eric (CERN) ; Chrysalidis, Katerina (CERN) ; Cocolios, Thomas E (Leuven U.) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Fedosseev, Valentin N (CERN) ; Hurier, Sophie (Leuven U. ; SCK-CEN, Mol) ; Lambert, Laura (CERN) ; Leenders, Benji (Leuven U. ; SCK-CEN, Mol ; Gent U.) ; Marsh, Bruce A (CERN) et al.
Thulium-167 is a promising radionuclide for nuclear medicine applications with potential use for both diagnosis and therapy (“theragnostics”) in disseminated tumor cells and small metastases, due to suitable gamma-line as well as conversion/Auger electron energies. However, adequate delivery methods are yet to be developed and accompanying radiobiological effects to be investigated, demanding the availability of $^{167}$Tm in appropriate activities and quality. [...]
2021
- Published in : Frontiers in Medicine 8 (2021) 712374
Fulltext: PDF;
|
|